What is Air?
Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease)
Welcome to
Clinical Research Platform
At Chiesi, we aim to deliver unique treatments. They're tailored to people's needs to improve their health and quality of life.
Clinical research is crucial to Chiesi's mission. But understanding if clinical research is right for you or your loved ones can feel like navigating a maze. That's why we've created this platform. It offers a clear path between people and researchers studying new treatments.
Whether you're a patient exploring treatment options, a caregiver seeking opportunities for a loved one, a healthcare professional researching clinical trials for a patient, or a healthcare professional interested in clinical research, this platform may provide you with information you’re looking for.
Together, we can shape the future of healthcare and make a difference!
Explore our Featured Clinical Trials
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Efficacy and Safety of tanimilast in asthmatics uncontrolled on ICS-containing background Maintenance Therapy
LAMPO (0-3): Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
About Us
Chiesi Farmaceutici is an international biopharmaceutical company with over 85 years of experience. We focus on developing innovative solutions in respiratory health (AIR), rare diseases (RARE) and speciality care (CARE) and clinical trials play an enormous part of this development.
What is Care?
The Care brand pillar is our portfolio of products and services related to special care and consumer healthcare. It includes:
Neonatology -products for the care of premature infants;
Special Care - products provided and administered to patients by medical professionals to treat their specific, chronic conditions;
Consumer Healthcare – Healthcare products sold directly to the consumer.
What is Rare?
Finding therapy can be difficult for patients who are struggling with a rare disease. Because it’s rare, they may have few, or no treatment options or specialists to turn to. At Chiesi Global Rare Diseases, we’re revolutionizing how we think about rare diseases.
Our focus is on finding therapies for the following key rare disease areas: Rare Dermatology, Rare Endo-Metabolic, Rare Inborn Errors of Metabolism, Rare Hematology, Rare Immunodeficiency, Rare Ophthalmology.
Sustainability
As a registered Benefit Corporation and the largest global biopharmaceutical group to be awarded B Corp™ Certification, Chiesi Group has taken active steps to formalize and apply its commitment to long-term sustainability and as a pharmaceutical company this gives us a dual role: taking care of our patients, but also of the environment.
We support continuous research, investing in innovation to create more effective and environmentally friendly products while enhancing and preserving patient health read more.